Erythropoiesis-stimulating agents to reduce heart failure hospitalization: a systematic review and meta-analysis
ESA treatment in patients with CHF and mild anaemia can reduce recurrent CHF hospitalization and improve functional capacity, without any impact on adverse events. Including ESAs in CHF management could be considered in patients with anaemia at high risk of recurrent hospital admissions.
Authors
- Karina V Bunting (ORCID: https://orcid.org/0000-0003-4602-4377)
- Otilia Țica (ORCID: https://orcid.org/0000-0002-6019-122X)
- Marcus Flather (ORCID: https://orcid.org/0000-0001-5644-3116)
- Madeleine Perrett
- Dirk J van Veldhuisen
- Asgher Champsi
- Thomas G von Lueder
Institutions
- Oslo University Hospital (NO)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University Medical Center Groningen (NL)
- Norfolk and Norwich University Hospital (GB)
- University Medical Center Utrecht (NL)
- County Hospital (GB)
- NIHR Birmingham Biomedical Research Centre (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1093/ejhf/xuaf012
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00